Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized dosing has led to development of methods to estimate MPA area under the curve based on the measurement of drug conc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bergan, Stein (VerfasserIn) , Brunet, Mercè (VerfasserIn) , Hesselink, Dennis A. (VerfasserIn) , Johnson-Davis, Kamisha L. (VerfasserIn) , Kunicki, Pawel K. (VerfasserIn) , Lemaitre, Florian (VerfasserIn) , Marquet, Pierre (VerfasserIn) , Molinaro, Mariadelfina (VerfasserIn) , Noceti, Ofelia (VerfasserIn) , Pattanaik, Smita (VerfasserIn) , Pawinski, Tomasz (VerfasserIn) , Seger, Christoph (VerfasserIn) , Shipkova, Maria (VerfasserIn) , Swen, Jesse J. (VerfasserIn) , van Gelder, Teun (VerfasserIn) , Venkataramanan, Raman (VerfasserIn) , Wieland, Eberhard (VerfasserIn) , Woillard, Jean-Baptiste (VerfasserIn) , Zwart, Tom C. (VerfasserIn) , Barten, Markus J. (VerfasserIn) , Budde, Klemens (VerfasserIn) , Dieterlen, Maja-Theresa (VerfasserIn) , Elens, Laure (VerfasserIn) , Haufroid, Vincent (VerfasserIn) , Masuda, Satohiro (VerfasserIn) , Millan, Olga (VerfasserIn) , Mizuno, Tomoyuki (VerfasserIn) , Moes, Dirk J. A. R. (VerfasserIn) , Oellerich, Michael (VerfasserIn) , Picard, Nicolas (VerfasserIn) , Salzmann, Linda (VerfasserIn) , Tönshoff, Burkhard (VerfasserIn) , van Schaik, Ron H. N. (VerfasserIn) , Vethe, Nils Tore (VerfasserIn) , Vinks, Alexander A. (VerfasserIn) , Wallemacq, Pierre (VerfasserIn) , Åsberg, Anders (VerfasserIn) , Langman, Loralie J. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: Apr 1, 2021
In: Therapeutic drug monitoring
Year: 2021, Jahrgang: 43, Heft: 2, Pages: 150-200
ISSN:1536-3694
DOI:10.1097/FTD.0000000000000871
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/FTD.0000000000000871
Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/drug-monitoring/Fulltext/2021/04000/Personalized_Therapy_for_Mycophenolate__Consensus.3.aspx
Volltext
Verfasserangaben:Stein Bergan, PhD, Mercè Brunet, PharmD, PhD, Dennis A. Hesselink, MD, PhD, Kamisha L. Johnson-Davis, PhD, Paweł K. Kunicki, PharmD, PhD, Florian Lemaitre, PharmD, PhD, Pierre Marquet, MD, PhD, Mariadelfina Molinaro, MSciBiol, Ofelia Noceti, PharmD, PhD,Smita Pattanaik, MD, Tomasz Pawinski, PharmD, PhD, Christoph Seger, PD, PhD, FAMH, Maria Shipkova, MD, FEBLM/MB, Jesse J. Swen, PhD, Teun van Gelder, PhD, Raman Venkataramanan, PhD, Eberhard Wieland, MD, FEBLM/MB, EupSpLM, Jean-Baptiste Woillard, PharmD, PhD, Tom C. Zwart, PharmD, Markus J. Barten, MD, PhD, Klemens Budde, MD, Maja-Theresa Dieterlen, RNDr, Laure Elens, PhD, Vincent Haufroid, PhD, Satohiro Masuda, PhD, Olga Millan, PhD, Tomoyuki Mizuno, PhD, Dirk J.A.R. Moes, PharmD, PhD, Michael Oellerich, MD, Nicolas Picard, PharmD, PhD, Linda Salzmann, MSc, Burkhard Tönshoff, MD, PhD, Ron H.N. van Schaik, MD, Nils Tore Vethe, PhD, Alexander A. Vinks, PharmD, PhD, Pierre Wallemacq, PhD, Anders Åsberg, PhD, and Loralie J. Langman, PhD

MARC

LEADER 00000caa a2200000 c 4500
001 1768344019
003 DE-627
005 20230426135753.0
007 cr uuu---uuuuu
008 210901s2021 xx |||||o 00| ||eng c
024 7 |a 10.1097/FTD.0000000000000871  |2 doi 
035 |a (DE-627)1768344019 
035 |a (DE-599)KXP1768344019 
035 |a (OCoLC)1341420556 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bergan, Stein  |e VerfasserIn  |0 (DE-588)1240344252  |0 (DE-627)1768342725  |4 aut 
245 1 0 |a Personalized therapy for mycophenolate  |b consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology  |c Stein Bergan, PhD, Mercè Brunet, PharmD, PhD, Dennis A. Hesselink, MD, PhD, Kamisha L. Johnson-Davis, PhD, Paweł K. Kunicki, PharmD, PhD, Florian Lemaitre, PharmD, PhD, Pierre Marquet, MD, PhD, Mariadelfina Molinaro, MSciBiol, Ofelia Noceti, PharmD, PhD,Smita Pattanaik, MD, Tomasz Pawinski, PharmD, PhD, Christoph Seger, PD, PhD, FAMH, Maria Shipkova, MD, FEBLM/MB, Jesse J. Swen, PhD, Teun van Gelder, PhD, Raman Venkataramanan, PhD, Eberhard Wieland, MD, FEBLM/MB, EupSpLM, Jean-Baptiste Woillard, PharmD, PhD, Tom C. Zwart, PharmD, Markus J. Barten, MD, PhD, Klemens Budde, MD, Maja-Theresa Dieterlen, RNDr, Laure Elens, PhD, Vincent Haufroid, PhD, Satohiro Masuda, PhD, Olga Millan, PhD, Tomoyuki Mizuno, PhD, Dirk J.A.R. Moes, PharmD, PhD, Michael Oellerich, MD, Nicolas Picard, PharmD, PhD, Linda Salzmann, MSc, Burkhard Tönshoff, MD, PhD, Ron H.N. van Schaik, MD, Nils Tore Vethe, PhD, Alexander A. Vinks, PharmD, PhD, Pierre Wallemacq, PhD, Anders Åsberg, PhD, and Loralie J. Langman, PhD 
264 1 |c Apr 1, 2021 
300 |a 51 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 01.09.2021 
520 |a When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized dosing has led to development of methods to estimate MPA area under the curve based on the measurement of drug concentrations in only a few samples. This approach is feasible in the clinical routine and has proven successful in terms of correlation with outcome. However, the search for superior correlates has continued, and numerous studies in search of biomarkers that could better predict the perfect dosage for the individual patient have been published. As it was considered timely for an updated and comprehensive presentation of consensus on the status for personalized treatment with MPA, this report was prepared following an initiative from members of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Topics included are the criteria for analytics, methods to estimate exposure including pharmacometrics, the potential influence of pharmacogenetics, development of biomarkers, and the practical aspects of implementation of target concentration intervention. For selected topics with sufficient evidence, such as the application of limited sampling strategies for MPA area under the curve, graded recommendations on target ranges are presented. To provide a comprehensive review, this report also includes updates on the status of potential biomarkers including those which may be promising but with a low level of evidence. In view of the fact that there are very few new immunosuppressive drugs under development for the transplant field, it is likely that MPA will continue to be prescribed on a large scale in the upcoming years. Discontinuation of therapy due to adverse effects is relatively common, increasing the risk for late rejections, which may contribute to graft loss. Therefore, the continued search for innovative methods to better personalize MPA dosage is warranted. 
700 1 |a Brunet, Mercè  |e VerfasserIn  |4 aut 
700 1 |a Hesselink, Dennis A.  |e VerfasserIn  |4 aut 
700 1 |a Johnson-Davis, Kamisha L.  |e VerfasserIn  |4 aut 
700 1 |a Kunicki, Pawel K.  |e VerfasserIn  |4 aut 
700 1 |a Lemaitre, Florian  |e VerfasserIn  |4 aut 
700 1 |a Marquet, Pierre  |e VerfasserIn  |4 aut 
700 1 |a Molinaro, Mariadelfina  |e VerfasserIn  |4 aut 
700 1 |a Noceti, Ofelia  |e VerfasserIn  |4 aut 
700 1 |a Pattanaik, Smita  |e VerfasserIn  |4 aut 
700 1 |a Pawinski, Tomasz  |e VerfasserIn  |4 aut 
700 1 |a Seger, Christoph  |e VerfasserIn  |4 aut 
700 1 |a Shipkova, Maria  |e VerfasserIn  |4 aut 
700 1 |a Swen, Jesse J.  |e VerfasserIn  |4 aut 
700 1 |a van Gelder, Teun  |e VerfasserIn  |4 aut 
700 1 |a Venkataramanan, Raman  |e VerfasserIn  |4 aut 
700 1 |a Wieland, Eberhard  |e VerfasserIn  |4 aut 
700 1 |a Woillard, Jean-Baptiste  |e VerfasserIn  |4 aut 
700 1 |a Zwart, Tom C.  |e VerfasserIn  |4 aut 
700 1 |a Barten, Markus J.  |e VerfasserIn  |4 aut 
700 1 |a Budde, Klemens  |e VerfasserIn  |4 aut 
700 1 |a Dieterlen, Maja-Theresa  |e VerfasserIn  |4 aut 
700 1 |a Elens, Laure  |e VerfasserIn  |4 aut 
700 1 |a Haufroid, Vincent  |e VerfasserIn  |4 aut 
700 1 |a Masuda, Satohiro  |e VerfasserIn  |4 aut 
700 1 |a Millan, Olga  |e VerfasserIn  |4 aut 
700 1 |a Mizuno, Tomoyuki  |e VerfasserIn  |4 aut 
700 1 |a Moes, Dirk J. A. R.  |e VerfasserIn  |4 aut 
700 1 |a Oellerich, Michael  |e VerfasserIn  |4 aut 
700 1 |a Picard, Nicolas  |e VerfasserIn  |4 aut 
700 1 |a Salzmann, Linda  |e VerfasserIn  |4 aut 
700 1 |a Tönshoff, Burkhard  |e VerfasserIn  |0 (DE-588)1032445823  |0 (DE-627)738463493  |0 (DE-576)173494196  |4 aut 
700 1 |a van Schaik, Ron H. N.  |e VerfasserIn  |4 aut 
700 1 |a Vethe, Nils Tore  |e VerfasserIn  |4 aut 
700 1 |a Vinks, Alexander A.  |e VerfasserIn  |4 aut 
700 1 |a Wallemacq, Pierre  |e VerfasserIn  |4 aut 
700 1 |a Åsberg, Anders  |e VerfasserIn  |4 aut 
700 1 |a Langman, Loralie J.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Therapeutic drug monitoring  |d Philadelphia, Pa. : Lippincott Williams & Wilkins, 1979  |g 43(2021), 2, Seite 150-200  |h Online-Ressource  |w (DE-627)330079239  |w (DE-600)2048919-5  |w (DE-576)094529795  |x 1536-3694  |7 nnas  |a Personalized therapy for mycophenolate consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology 
773 1 8 |g volume:43  |g year:2021  |g number:2  |g pages:150-200  |g extent:51  |a Personalized therapy for mycophenolate consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology 
856 4 0 |u https://doi.org/10.1097/FTD.0000000000000871  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://journals.lww.com/drug-monitoring/Fulltext/2021/04000/Personalized_Therapy_for_Mycophenolate__Consensus.3.aspx  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210901 
993 |a Article 
994 |a 2021 
998 |g 1032445823  |a Tönshoff, Burkhard  |m 1032445823:Tönshoff, Burkhard  |d 910000  |d 910500  |d 50000  |e 910000PT1032445823  |e 910500PT1032445823  |e 50000PT1032445823  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 32 
999 |a KXP-PPN1768344019  |e 3972364830 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"part":{"volume":"43","text":"43(2021), 2, Seite 150-200","extent":"51","year":"2021","pages":"150-200","issue":"2"},"pubHistory":["1.1979 -"],"language":["eng"],"recId":"330079239","disp":"Personalized therapy for mycophenolate consensus report by the International Association of Therapeutic Drug Monitoring and Clinical ToxicologyTherapeutic drug monitoring","note":["Gesehen am 11.06.2019"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Therapeutic drug monitoring","subtitle":"official journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","title":"Therapeutic drug monitoring"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["330079239"],"zdb":["2048919-5"],"issn":["1536-3694"]},"origin":[{"publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedKey":"1979","dateIssuedDisp":"1979-","publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar]"}]}],"physDesc":[{"extent":"51 S."}],"id":{"eki":["1768344019"],"doi":["10.1097/FTD.0000000000000871"]},"origin":[{"dateIssuedDisp":"Apr 1, 2021","dateIssuedKey":"2021"}],"name":{"displayForm":["Stein Bergan, PhD, Mercè Brunet, PharmD, PhD, Dennis A. Hesselink, MD, PhD, Kamisha L. Johnson-Davis, PhD, Paweł K. Kunicki, PharmD, PhD, Florian Lemaitre, PharmD, PhD, Pierre Marquet, MD, PhD, Mariadelfina Molinaro, MSciBiol, Ofelia Noceti, PharmD, PhD,Smita Pattanaik, MD, Tomasz Pawinski, PharmD, PhD, Christoph Seger, PD, PhD, FAMH, Maria Shipkova, MD, FEBLM/MB, Jesse J. Swen, PhD, Teun van Gelder, PhD, Raman Venkataramanan, PhD, Eberhard Wieland, MD, FEBLM/MB, EupSpLM, Jean-Baptiste Woillard, PharmD, PhD, Tom C. Zwart, PharmD, Markus J. Barten, MD, PhD, Klemens Budde, MD, Maja-Theresa Dieterlen, RNDr, Laure Elens, PhD, Vincent Haufroid, PhD, Satohiro Masuda, PhD, Olga Millan, PhD, Tomoyuki Mizuno, PhD, Dirk J.A.R. Moes, PharmD, PhD, Michael Oellerich, MD, Nicolas Picard, PharmD, PhD, Linda Salzmann, MSc, Burkhard Tönshoff, MD, PhD, Ron H.N. van Schaik, MD, Nils Tore Vethe, PhD, Alexander A. Vinks, PharmD, PhD, Pierre Wallemacq, PhD, Anders Åsberg, PhD, and Loralie J. Langman, PhD"]},"recId":"1768344019","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 01.09.2021"],"title":[{"title_sort":"Personalized therapy for mycophenolate","subtitle":"consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","title":"Personalized therapy for mycophenolate"}],"person":[{"given":"Stein","family":"Bergan","role":"aut","roleDisplay":"VerfasserIn","display":"Bergan, Stein"},{"display":"Brunet, Mercè","roleDisplay":"VerfasserIn","role":"aut","family":"Brunet","given":"Mercè"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Hesselink, Dennis A.","given":"Dennis A.","family":"Hesselink"},{"roleDisplay":"VerfasserIn","display":"Johnson-Davis, Kamisha L.","role":"aut","family":"Johnson-Davis","given":"Kamisha L."},{"given":"Pawel K.","family":"Kunicki","role":"aut","roleDisplay":"VerfasserIn","display":"Kunicki, Pawel K."},{"family":"Lemaitre","given":"Florian","display":"Lemaitre, Florian","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Pierre","family":"Marquet","role":"aut","roleDisplay":"VerfasserIn","display":"Marquet, Pierre"},{"family":"Molinaro","given":"Mariadelfina","roleDisplay":"VerfasserIn","display":"Molinaro, Mariadelfina","role":"aut"},{"given":"Ofelia","family":"Noceti","role":"aut","roleDisplay":"VerfasserIn","display":"Noceti, Ofelia"},{"given":"Smita","family":"Pattanaik","role":"aut","roleDisplay":"VerfasserIn","display":"Pattanaik, Smita"},{"given":"Tomasz","family":"Pawinski","role":"aut","display":"Pawinski, Tomasz","roleDisplay":"VerfasserIn"},{"family":"Seger","given":"Christoph","display":"Seger, Christoph","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Shipkova, Maria","role":"aut","family":"Shipkova","given":"Maria"},{"role":"aut","display":"Swen, Jesse J.","roleDisplay":"VerfasserIn","given":"Jesse J.","family":"Swen"},{"display":"van Gelder, Teun","roleDisplay":"VerfasserIn","role":"aut","family":"van Gelder","given":"Teun"},{"family":"Venkataramanan","given":"Raman","display":"Venkataramanan, Raman","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Eberhard","family":"Wieland","role":"aut","roleDisplay":"VerfasserIn","display":"Wieland, Eberhard"},{"family":"Woillard","given":"Jean-Baptiste","display":"Woillard, Jean-Baptiste","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Zwart, Tom C.","roleDisplay":"VerfasserIn","given":"Tom C.","family":"Zwart"},{"given":"Markus J.","family":"Barten","role":"aut","roleDisplay":"VerfasserIn","display":"Barten, Markus J."},{"family":"Budde","given":"Klemens","display":"Budde, Klemens","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Maja-Theresa","family":"Dieterlen","role":"aut","roleDisplay":"VerfasserIn","display":"Dieterlen, Maja-Theresa"},{"family":"Elens","given":"Laure","roleDisplay":"VerfasserIn","display":"Elens, Laure","role":"aut"},{"given":"Vincent","family":"Haufroid","role":"aut","roleDisplay":"VerfasserIn","display":"Haufroid, Vincent"},{"family":"Masuda","given":"Satohiro","display":"Masuda, Satohiro","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Millan, Olga","roleDisplay":"VerfasserIn","given":"Olga","family":"Millan"},{"role":"aut","display":"Mizuno, Tomoyuki","roleDisplay":"VerfasserIn","given":"Tomoyuki","family":"Mizuno"},{"given":"Dirk J. A. R.","family":"Moes","role":"aut","display":"Moes, Dirk J. A. R.","roleDisplay":"VerfasserIn"},{"given":"Michael","family":"Oellerich","role":"aut","roleDisplay":"VerfasserIn","display":"Oellerich, Michael"},{"given":"Nicolas","family":"Picard","role":"aut","display":"Picard, Nicolas","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Salzmann, Linda","role":"aut","family":"Salzmann","given":"Linda"},{"display":"Tönshoff, Burkhard","roleDisplay":"VerfasserIn","role":"aut","family":"Tönshoff","given":"Burkhard"},{"family":"van Schaik","given":"Ron H. N.","roleDisplay":"VerfasserIn","display":"van Schaik, Ron H. N.","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Vethe, Nils Tore","given":"Nils Tore","family":"Vethe"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Vinks, Alexander A.","given":"Alexander A.","family":"Vinks"},{"given":"Pierre","family":"Wallemacq","role":"aut","display":"Wallemacq, Pierre","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Åsberg, Anders","role":"aut","family":"Åsberg","given":"Anders"},{"family":"Langman","given":"Loralie J.","display":"Langman, Loralie J.","roleDisplay":"VerfasserIn","role":"aut"}]} 
SRT |a BERGANSTEIPERSONALIZ1202